

A preclinical model of THC edibles that produces high-dose cannabimimetic responses

Reviewed Preprint

Revised by authors after peer review.

About eLife's process

Reviewed preprint version 2

December 21, 2023 (this version)

Reviewed preprint version 1

October 9, 2023

Posted to preprint server

September 1, 2023

Sent for peer review

August 11, 2023

Anthony English, Fleur Uittenbogaard, Alexa Torrens, Dennis Sarroza, Anna Slaven, Danielle Piomelli, Michael R. Bruchas, Nephi Stella , Benjamin B. Land 

Departments of Pharmacology, University of Washington, Seattle WA 98195 • UW Center of Excellence in Neurobiology of Addiction, Pain, and Emotion (NAPE), University of Washington, Seattle WA 98195 • Center for Cannabis Research, University of Washington, Seattle WA 98195 • Department of Anatomy & Neurobiology, University of California Irvine, Irvine CA • Psychiatry & Behavioral Sciences, University of Washington, Seattle WA 98195

 https://en.wikipedia.org/wiki/Open_access

 Copyright information

Abstract

No preclinical experimental approach enables the study of voluntary oral consumption of high-concentration Δ^9 -tetrahydrocannabinol (THC) and its intoxicating effects, mainly owing to the aversive response of rodents to THC that limits intake. Here we developed a palatable THC formulation and an optimized access paradigm in mice to drive voluntary consumption. THC was formulated in chocolate gelatin (THC-E-gel). Adult male and female mice were allowed *ad libitum* access for 1 and 2 h. Cannabimimetic responses (hypolocomotion, analgesia, and hypothermia) were measured following access. Levels of THC and its metabolites were measured in blood and brain tissue. Acute acoustic startle responses were measured to investigate THC-induced psychotomimetic behavior.

When allowed access for 2 h to THC-E-gel on the second day of a three-day exposure paradigm, adult mice consumed up to ≈ 30 mg/kg over 2 h which resulted in robust cannabimimetic behavioral responses (hypolocomotion, analgesia and hypothermia). Consumption of the same gelatin decreased on the following 3rd day of exposure. Pharmacokinetic analysis show that THC-E-gel consumption led to parallel accumulation of THC and its psychoactive metabolite, 11-OH-THC, in brain, a profile that contrasts with the known rapid decline in brain 11-OH-THC levels following THC intraperitoneal (*i.p.*) injections. THC-E-gel consumption increased the acoustic startle response in males but not in females, demonstrating a sex-dependent effect of consumption. Thus, while voluntary consumption of THC-E-gel triggered equivalent cannabimimetic responses in male and female mice, it potentiated acoustic startle responses preferentially in males. We build a dose-prediction model that included cannabimimetic behavioral responses elicited by *i.p.* versus THC-E-gel to test the accuracy and generalizability of this experimental approach and found that it closely predicted the measured acoustic startle results in males and females. In summary, THC-E-gel offers a robust preclinical experimental approach to study cannabimimetic responses triggered by voluntary consumption in mice, including sex-dependent psychotomimetic responses.

eLife assessment

This **important** study presents the validation of an oral delta9-tetrahydrocannabinol (THC) consumption mouse model utilizing highly palatable e-capsule gelatin. The results **convincingly** demonstrate that oral consumption produced THC behavioral and physiological effects, as well as measurable brain levels. The utility of the model for chronic consumption remains to be determined. The authors have clearly acknowledged limitations of their model and areas for future study and development. As the field of cannabinoid research moves toward application of routes of administration that mimic human use, these model systems will be increasingly **important** in assessing the effects of cannabinoid-based drugs.

Introduction

The use of *Cannabis* products containing high concentrations of THC is rapidly increasing despite our limited understanding of its potential impact on physical and mental health [1–3]. These products are typically inhaled as combusted plant matter, vaporized extracts, or consumed in edible formulations. THC acts as a partial agonist at cannabinoid 1 receptors (CB₁R) to trigger a myriad of responses such as physiological responses (e.g., increase heart rate), altered mood and time perception, inhibition of motor control, and impaired learning and memory [4–10]. Subsequently, a relationship between *Cannabis* and psychotic/affective symptoms and an observable increase in *Cannabis*-associated vehicle crashes has become apparent without an understanding of the neural effects of higher dose THC [6,11–14]. Many of these effects translate to preclinical models where in rodents, THC reduces spontaneous locomotion and locomotor control, induces hypersensitivity to tactile and auditory stimuli, ataxia, and sedation; all of which have been shown to be mediated through action at CB₁R [15–18]. Importantly, some cannabimimetic responses are sex-dependent, as exemplified by the finding that THC (5 mg/kg, *i.p.*) triggers a more pronounced reduction in spontaneous locomotion and anxiogenic response in females than in males [19,20]. In addition to these cannabimimetic responses, preclinical investigations have pursued psychosis-related behaviors through the acoustic startle response, finding that involuntary administration of THC impairs psychomotor/sensorimotor gaiting [21–24], emphasizing the translational value in understanding THC's bioactivity in humans.

Understanding the effects of increased THC use in humans through preclinical models of voluntary THC administration has proven difficult to establish due to the aversive behaviors to higher doses in rodent models [25,26]. In recent years, progress has been made in promoting voluntary oral consumption of THC in rodents, but results have been limited to mild, acute CB₁R-dependent cannabimimetic responses [27–29]. This lack of experimental tools to translate higher-dose THC intake in humans to preclinical models emphasizes the urgent need to develop and fully characterize a novel experimental approach. To bridge this translational gap, we initially developed an approach where mice are given *ad libitum* access to consume a sugar-water gelatin (CTR-gel) containing fixed amounts of THC [28,30]. Matching previous rodent studies, we found that mice consumed more vehicle gelatin than THC gelatin, indicating that they detected and avoided THC [31]. To overcome this limitation, in the current study we developed and characterized a palatable oral gelatin formulation that increases voluntary consumption by formulating THC in a chocolate-flavored nutritional shake, Ensure™ (E-gel). Previous work has shown that mice have a preference for chocolate flavor, making it an ideal THC formulant to increase palatability [32,33]. We leveraged this approach to determine whether oral consumption of high concentration THC gelatin induces commonly studied cannabimimetic responses in mice (hypolocomotion, analgesia, and hypothermia) and then we examined the

effects of THC E-gel consumption on acoustic startle response, a preclinical measure of reflexive response rate and psychomotor arousal [22,34]. The model developed here leverages acute voluntary consumption of a sweetened gelatin to investigate psychomotor and reflexive behaviors, pharmacokinetics, and triad responses following consumption of THC E-gel in mice.

Materials and Methods

Animal Studies

Animal studies followed the guidelines established by AAALAC and were approved by IACUC of the University of Washington. Male and female C57BL/6J mice ranging from 8-14 weeks of age were used. Animals were housed with sibling littermates and were provided with standard chow and water, *ad libitum*, and without any additional environmental enrichment. Investigators were not blinded to experimental exposure conditions throughout assays due to the noticeable behavioral effects measured in response to THC. Animal procedures were approved by the Institutional Animal Care and Use Committee of the University of Washington and conform to the guidelines on the care and use of animals by the National Institutes of Health.

Pharmacological Agents

Animals received THC (0.1, 0.3, 1, 3, 5, 10, and 30 mg/kg) and SR141716 (**SR1**, 1 mg/kg) *i.p.* or were exposed to THC suspended in gelatin. THC and SR141716 (SR1) were provided by the National Institute of Drugs abuse Drug Supply Program (Bethesda, MD). THC in ethanol (50 mg/ml) was either added to gelatin mixtures (CTR or Ensure®) or prepared for *i.p.* injection. For *i.p.* injection, both THC (0.1, 0.3, 1, 3, 5, 10, and 30 mg/kg) and SR1 (1mg/kg) were dissolved in 95% ethanol and then vortexed thoroughly with equal volume Cremophor and finally dissolved in sterile saline to reach a final 1:1:18 solution consisting of ethanol:cremophor:saline.

Gelatin formulation

Control gelatin (CTR-gel)

Deionized water (100 mL) was warmed to 40°C and stirred at a constant rate. 2.5 g of Polycal™ sugar and 3.85 g of Knox™ Gelatin were added and the mixture was maintained at a temperature below 43°C. The mixture was removed from heat, and THC (50 mg/ml in ethanol) was added to reach a concentration of 0.3, 1, 2, or 4 mg/15 ml. An equal volume of ethanol was added to vehicle gelatin (<1% total volume). Gelatin was poured into plastic cups ranging from 2-10 ml and set into a 4°C fridge to solidify overnight.

Ensure gelatin (E-gel)

Chocolate-flavored Ensure™ (100 ml) was warmed to 40°C and stirred at a constant rate. 3.85 g of Knox™ Gelatin were added and the mixture was maintained at a temperature below 43°C. The mixture was removed from heat and THC (50 mg/15 ml ethanol) was added to reach a concentration of 1, 2, 5, or 10 mg/15 ml. At the 10 mg/15 ml concentration, ethanol was evaporated off to 50% volume before being added to the mixture to reduce total alcohol concentration below 1%. An equal volume of ethanol was added to vehicle gelatin (<1% total volume). Gelatin was poured into plastic cups ranging from 2-10 ml and set into a 4°C fridge to solidify overnight. Mice were always exposed to more gelatin than they could consume, smaller volumes were used to conserve THC.

Acute gelatin access

Animals were first habituated to gelatin by receiving an excess of gelatin in their home cage the day before the first timed access. On the first day of access, mice were placed into a home cage-like environment equipped with a vehicle gelatin cup that was stabilized to the cage. Behavior was recorded during the consumption window via an overhead camera. On the second day of access, animals were placed into the same gelatin access cage with either a vehicle or THC gelatin cup. Animals experienced either a triad of behaviors (open field, tail flick, and body temperature) measured immediately preceding and following the consumption window or an acoustic startle trial immediately following consumption. On the third and final day of access animals were placed into the same cage with a vehicle gelatin cup. For all gelatin access days, gelatin cups and animals were weighed before and after the consumption window. Access to gelatin during the consumption window was limited to either 1 or 2 h after which the animals were removed and returned to their home cage.

Triad of Cannabimimetic behaviors

Hypolocomotion, hypothermia, and analgesia were measured 1 h post-*i.p.* injection or immediately following gelatin exposure. Pre-tests were collected immediately prior to injection or gelatin exposure.

Open Field

A 50 cm x 50 cm chamber (25 LUX) was equipped with an overhead camera to record movement. Animals were placed in the chamber for 15 minutes and then returned to their home cage. Total distance traveled (cm) was measured using Noldus Ethovision behavioral tracking software. Locomotion behavior was measured immediately before and after gelatin access to calculate a gelatin dependent difference score (post-pre). Pre-test measurements for CTR-gel were not collected and pre-test values were instead normalized to vehicle post-tests to produce a difference score as Post-VEH.

Tail Flick Analgesia

A hot water bath was set to 52.5°C. Mice were securely held upright in the air with their tail hanging downward. A timer was started as 75% of their tail was submerged into the water. Time was measured once a painful response was presented, marked as a latency to flick their tail out of the hot water. Tail flick responses were measured immediately before and after gelatin access to calculate a gelatin-dependent difference score (post-pre).

Measuring body temperature

Animals were placed on a stable surface with their tails lifted. A rectal thermometer probe (RET-3 Kent Scientific) was inserted into the anus for 10-20 s until the temperature recording stabilized. This test was always performed prior to the Tail Flick test to reduce any potential temperature contamination effects. Body temperatures were measured immediately before and after gelatin access to calculate a gelatin dependent difference score (post-pre).

Blood and brain tissue collection and quantification

Animals underwent the same gelatin access paradigm for day 1 and 2 described in acute gelatin access. After 2 h of gelatin access, blood was collected by cardiac puncture with a 23-gauge needle and placed on ice. Immediately following, brain tissue was collected and flash frozen in liquid nitrogen. Blood samples were spun in a 4°C centrifuge at 1450 x *g* for 15 min. Plasma was transferred to another tube and stored alongside brain samples in -80°C until being shipped on dry ice to the Piomelli Lab at UCI for sample analysis. Samples were collected immediately following 1

and 2 h gelatin access and 30 min and 24 h after 2 h gelatin access. THC and its first-pass metabolites 11-OH-THC and 11-COOH-THC were quantified in plasma and brain tissue using a selective isotope-dilution liquid chromatography/tandem mass spectrometry assay (26). Concentration data after E-gel consumption were compared to blood and brain tissue concentrations after *i.p.* administration from previous publications from the Piomelli Lab [35].

Acoustic startle

Acoustic Startle behaviors were measured after 1 or 2 h THC-E-gel exposure (10 mg/15 ml) and THC-*i.p.* (0.1, 1, 5, 10 mg/kg) injection. Sound-buffered startle chambers (SR-Lab, San Diego Instruments) were used to measure acoustic startle responses, equipped with a holding tube and an accelerometer. Background sound was maintained at 65 dB from a high-frequency speaker producing white noise. Startle tests were conducted 1 h post-THC-*i.p.* injection or immediately following THC-E-gel exposure. Animals were set in the holding tube for 5 min to habituate prior to a series of seven trials presenting escalating sound levels of null, 80, 90, 100, 105, 110, and 120 dB. Tones were presented for 40 ms with an inter-trial interval of 30 s. Animals were only ever exposed to the acoustic startle paradigm once, immediately after gelatin access, to avoid auditory habituation.

Data/Statistical analysis

All data were analyzed using GraphPad Prism 10-11. For all statistical analyses (unpaired *t* test, one- and two-way ANOVA, and post hoc analyses), alpha level was set to 0.05. For all ANOVA analyses, Sidak's post-test was performed for increased power and repeated measures analysis was performed for time-dependent consumption data. All behavioral locomotor tracking was analyzed using Noldus Ethovision software and statistical analyses performed through GraphPad Prism 10-11. Nonlinear regressions (Figure 4B-d and Supplemental Figure S3B-G) were performed with a 3-parameter nonlinear, least squares, regression.

Results

E-gel promotes heightened voluntary oral consumption of THC and induces cannabimimetic behaviors by adult mice

To incentivize voluntary oral consumption of high concentration THC, we utilized an E-gel formulation and optimized an exposure paradigm based on previous studies [28,36]. Here, individual mice were exposed to a control (CTR-gel) during a 2 h consumption period (Habituation, Day 1); and the following day exposed to THC formulated in either CTR-gel or E-gel (X mg/15 ml) for 2 h (Figure 1a). Gelatin mass was measured before and after access to calculate grams consumed, and gelatin concentrations are expressed as X mg of THC (X = mg of THC/15 ml gelatin) (Figure 1b). As expected, higher concentrations of THC-CTR-gel reduced gelatin consumption, an effect significant at 1 mg THC (Figure 1c, One-way ANOVA $F_{4,108} = 9.126$, $p < 0.001$, Sidak's). Remarkably, 7/17 (41%) of mice exposed to 4 mg CTR-gel did not consume any gelatin while all mice consistently consumed 5 mg and 10 mg THC-E-gel (Figure 1d). Thus, mice consumed 1.9 ± 0.05 g of VEH-E-gel and 1.0 ± 0.07 g of E-gel containing THC (10 mg/15 ml) (Figure 1d, One-way ANOVA $F_{5,75} = 14.10$, $p < 0.001$, Sidak's). Note that mice consumed similar amounts of VEH-E-gel and VEH-CTR-gel (1.96 ± 0.15 g and 1.92 ± 0.17 g, respectively), indicating that chocolate flavor *per se* does not increase consumption. When calculating the amount of THC consumed in mg/kg, we found that mice consumed more THC when formulated in E-gel (Figures 1e). For example, mice consumed 10.5 ± 0.7 mg/kg/2 h when exposed to 2 mg E-gel compared to only 4.6 ± 0.5 mg/kg/2 h when exposed to the same amount of THC formulated in CTR-gel. Using this experimental approach, maximal consumption reached 29.2 ± 1.8 mg of THC per kg/2 h when exposed to E-gel containing THC (10 mg/15 ml), compared to the few mice that consumed only 8.4 ± 1.2 mg of THC per kg/2 h when exposed to CTR-gel containing THC (4 mg) (Figures 1e, Two-

way ANOVA $F_{7,94} = 73.14$, $p < 0.001$, Sidak's). As previously shown, we found no statistically significant sex-dependent effects in consumption between male and female mice across all treatments (Two-way ANOVA $F_{1,60} = 3.64$, $p < 0.06$) but did see an individual significance between males and females at 1 mg THC-E-gel (**Supplementary Figure S1**, Two-way ANOVA, $p < 0.05$) [28,30]. These data show that mice consistently consume significant quantities of E-gel despite high THC concentrations. Based on these results, we next focused our study on quantifying the pharmacological effects of THC formulated in E-gel.

Considering that THC-CTR-gel triggers mild cannabimimetic responses due to limited consumption [28,30], we determined whether consumption of THC-E-gel could induce cannabimimetic responses measured immediately following the 2 h access period (**Figure 1f**). Thus, we selected three well-described behavioral effects of THC in mice: hypolocomotion, analgesia, and hypothermia (**Figure 1g-i**) [17]. THC was formulated and administered either by *i.p.* injection (grey), CTR-gel (green), or E-gel (purple) and behavioral responses to gelatin consumption were plotted from the average dose consumed, calculated in **Figure 1e**. **Figure 1g** shows that *i.p.* administration of THC reduced locomotion starting at 3 mg/kg, as previously reported [17], and that this response was significant after access to 4 mg THC-CTR-gel (avg: 8.4 mg/kg) and 2 mg THC-E-gel (avg: 10.5 mg/kg) (**Supplementary Figure 2b, e**, One-way ANOVA $F_{5,68} = 14.54$, $p < 0.001$, Sidak's for CTR-gel and $F_{4,56} = 3.24$, $p = 0.02$ for E-gel, Sidak's). **Figure 1h** shows the greatest THC-induced analgesia was reached at 30 mg/kg *i.p.* and after access to 2 mg THC-E-gel (**Figure 1h** and **Supplementary Figure S2d, g**, One-way ANOVA $F_{4,104} = 9.4$, $p < 0.001$, Sidak's for CTR-gel and $F_{7,77} = 8.7$, $p < 0.001$ for E-gel, Sidak's). THC injection (*i.p.*) reduced core body temperature starting at 3 mg/kg, and that this response reached significance at 4 mg THC-CTR-gel (avg: 8.4 mg/kg) and at 5 mg THC-E-gel (avg: 17.2 mg/kg). **Figure 1i** also shows that reduced core body temperature induced by THC reached a significant effect of -5.84°C at 30 mg/kg *i.p.*, -1.5°C after 4 mg THC-CTR-gel (avg: 8.4mg/kg) and -1.8°C after 10 mg THC-E-gel (avg: 29.2 mg/kg) (**Supplementary Figure S2d, g**, One-way ANOVA $F_{5,61} = 11.16$, $p < 0.001$, Sidak's for CTR-gel and $F_{4,114} = 6.36$, $p < 0.001$ for E-gel, Sidak's). Analgesia and hypothermia did not plateau, matching prior studies which have also shown that 30 mg/kg THC-*i.p.* does not produce a maximal response for these cannabimimetic behaviors [37,38]. Sexual dimorphic responses were measured after THC administration through either *i.p.* injection or E-gel, although VEH-E-gel did show a significant difference in hypolocomotion between males and females (Supplementary Figure S3b-g, THC: Two-way ANOVA, Sidak's post-test, VEH-E-gel locomotion: Unpaired T-test, $t = 2.721$, $df = 16$, $p = 0.02$) Thus, **Figures 1g-i** show that: 1) THC reduces locomotion when administered using these three experimental paradigms, and to a greater extent at higher-dose *i.p.* THC and higher-concentration THC-E-gel; 2) THC induced analgesia only when administered *i.p.* and using THC-E-gel, though *i.p.* administration is more potent; and 3) THC reduces core body temperature only when administered *i.p.* and using THC-E-gel, though *i.p.* administration is more potent.

Next, we analyzed the cannabimimetic responses of individual mice following THC (10 mg/15 ml) E-gel access and how the CB₁R inverse agonist, SR1, administered 1 h into the consumption window influences these responses (**Figure 1j**). SR1 was administered at 1 h to reach peak circulating concentrations during the behavioral testing (1-2 h post-injection) and to reduce any anorectic effects that would inhibit consumption of THC-E-gel [39,40]. Cannabimimetic responses increased as a function (linear regression) of increasing amount of THC consumed, demonstrating a significant relationship between the amount of THC consumed and the three cannabimimetic readouts: hypolocomotion (linear regression $F_{1,46} = 9.74$, $p = 0.003$), Analgesia (linear regression, $F_{1,57} = 15.73$, $p < 0.001$), and hypothermia (linear regression, $F_{1,46} = 24.72$, $p < 0.001$) (**Figure 1k-m**). Confirming the involvement of CB₁R, SR1 blocked the three THC-induced cannabimimetic responses: hypolocomotion ($F_{1,6} = 4.1$, $p = 0.09$), Analgesia ($F_{1,6} = 0.66$, $p = 0.45$), and hypothermia (SR1: $F_{1,6} = 0.68$, $p = 0.44$) (**Figure 1k-m**). As expected, SR1-treated mice did not consume maximal THC-E-gel compared to some animals exposed to 10 mg THC-E-gel, likely due in part to the SR1 injection 1 h into the consumption window and the known anorectic effects of SR1 [39,40]. We additionally compared the linear regression of all THC-E-gel consumption within




Figure 1

E-gel promotes heightened voluntary oral consumption of THC and induces cannabinimimetic behaviors by adult mice.

a) Mice were given free access to vehicle (VEH), or THC formulated in either CTR-gel or E-gel for 2 h on Day 1 and Day 2. **b**) Consumption was determined by weighing gelatin at the end of each session. **c**) Consumption of CTR-gel on Day 2 is decreased after addition of THC. **d**) Consumption of E-gel on Day 2 is maintained after addition of THC. **e**) Dose of THC consumed, in mg/kg, when formulated in either CTR-gel or E-gel on Day 2. Results are mean $\pm$ S.E.M. Consumption compared ANOVA and Sidak's, * p <0.05, ** p <0.01, and *** p <0.001, N =8-40. **f**) Diagram of behavioral paradigm before and after *i.p.* or gelatin administration. **g-i**) Dose-dependent behavioral responses for hypolocomotion (**g**), analgesia (**h**), and hypothermia (**i**) after THC exposure. Administration by *i.p.* (grey) is plotted on x-axis by single bolus injection while CTR-gel (green) and E-gel (purple) are plotted based on average THC consumed after 2 h exposure window shown in **e**. **j**) Diagram of THC-E-gel exposure, behavioral measurements, and SR1 injection (by *i.p.*) at 1 h into exposure window. **k-m**) Individual behavioral responses for hypolocomotion (**k**), analgesia (**l**), and hypothermia (**m**) for each animal. Individual points are plotted based on individual THC consumption with a linear regression to show correlation between consumed THC and behavioral output (p-values: **k**=0.003, **l**<0.001, **m**<0.001). SR1 treated mice are plotted (red) based on consumed THC after exposure to 10 mg/15 ml THC-E-gel with a linear regression to show no correlation across three behaviors (p-values: **k**=0.09, **l**=0.44, **m**=0.45).

the range of SR1-treated animal consumption and found that THC-E-gel alone still produced a significant correlation to all behaviors. These results indicate that consumption of THC-E-gel evokes robust CB₁R-dependent cannabimimetic behavioral responses in adult mice that are comparable to *i.p.*-THC administration when measuring hypolocomotion, and less potent when compared to *i.p.*-THC administration when measuring analgesia and reduction in core body temperature.

THC-E-Gel reduces locomotion during the exposure period

We found that mice consumed ~2 g of vehicle E-gel (VEH-E-gel) compared to ~1 g of THC-E-gel (10 mg/15 ml), indicating a 2-fold reduction in consumption (**Figure 2a**). To investigate the time course of this effect, we weighed gelatin every 10 min during the 2 h access period in a 3-day paradigm: access to VEH-E-gel on Day 1, access to either VEH-E-gel or THC-E-gel Day 2, and access to VEH-E-gel on Day 3 (**Figure 2a**). **Figure 2b** shows that consumption of VEH-E-gel on Day 1 started within 20 min of availability and was constant during the 2 h period. On Day 2, mice consumed comparable amounts of VEH-E-gel and THC-E-gel during the initial 40 min of access (16.3 and 13.0 mg/min, respectively) (**Figure 2c** and **Supplementary Figure S4a**). However, consumption of THC-E-gel plateaued after 40 min to a rate of 4.2 mg/min (67.7% reduction), while consumption of VEH-E-gel was sustained at 9.9 mg/min (39.3% reduction), producing a significant effect by THC to modify gelatin consumption (**Figure 2c**, Two-way ANOVA, repeated measures $F_{1,14} = 7.604$, $p = 0.015$, Sidak's and **Supplementary Figure S4b**, Two-way ANOVA, $F_{1,14} = 6.05$, $p = 0.03$, Sidak's). By sharp contrast, mice that had consumed THC-E-gel the day prior consumed VEH-E-gel on Day 3 at a significantly slower rate (6.2 mg/min) during the access period, suggesting an aversive memory to THC-E-gel (**Figure 2d**, Two-way ANOVA, repeated measures $F_{1,14} = 4.865$, $p = 0.045$, Sidak's and **Supplementary Figure S4b**). Consequently, mice exposed to THC-E-gel on Day 2 significantly decreased their total VEH-E-gel consumption on Days 2 and 3 (**Figure 2e**, Two-way ANOVA, $F_{1,83} = 37.51$, $p < 0.001$, Sidak's). These data suggest that, on Day 2, mice consumed high enough quantities of THC to induce a typically *i.p.*-high-dose (5-10 mg/kg) cannabimimetic response resulting in an avoidance to gelatin on Day 3.

Reduced spontaneous locomotion is a hallmark response to THC in mice. To address whether THC-E-gel consumption impacts spontaneous locomotion, we video-recorded the travelling distance of mice during the gelatin access period (total distance in cm over 2 h) (**Figure 2f**). **Figure 2g-i** shows that locomotion during the consumption period initially reached (1,200 cm/ 5 min) and then steadily decreased over the 2 h session on Day 1, as expected in mice that are habituating to the environment. On Day 2, spontaneous locomotor activity between mice that consumed VEH-E-gel and THC-E-gel diverged after 40 min, showing a significant decrease in total locomotion in mice that consumed THC-E-gel (**Figure 2h**, Two-way ANOVA, repeated measures $F_{1,14} = 11.18$, $p = 0.005$, Sidak's). Thus, this reduction in locomotion parallels a corresponding reduction in consumption in **Figure 2e** that is significantly different on day 2 (**Figure 2j**, Two-way ANOVA, $F_{1,42} = 0.3413$, $p = 0.562$, Sidak's). Importantly, spontaneous locomotion of mice exposed to VEH-E-gel and THC-E-gel was similar on Day 3. Together, these results show that consumption of THC-E-gel induced hypolocomotion on Day 2 after 40 min of access. Additionally, the decreased consumption of VEH-E-gel on Day 3 is likely due to an aversive memory of the THC exposure period and not to hypolocomotion. Thus, E-gel incentivizes voluntary THC consumption to induce robust hypolocomotion, a hallmark cannabimimetic response, within 40 min of access.

Consumption of THC-E-gel results in concomitant increases in the levels of THC and its metabolites in brain tissue

Several studies have shown that the PK profile of THC (5 mg/kg, *i.p.*) results in peak circulating concentrations of THC (1000pmol/g), its bioactive metabolite 11-OH-THC (300pmol/g), and its inactive metabolite 11-COOH-THC (100 pmol/g) in the brain after 2 h [35,41]. To determine the PK profile of THC-E-gel consumption (10 mg/15 ml) and considering the hypolocomotion behavior occurring during the consumption window, we collected plasma and brain tissue




Figure 2

THC-E-gel consumption triggers CB₁R-dependent behaviors

a) Over a 3-day exposure paradigm, mice received 3 days of E-gel with either VEH or THC (10mg/15ml) E-gel on day 2. **b-d**) Cumulative gelatin consumption recorded every 10 minutes throughout the 2 h exposure window over the 3-day paradigm. VEH (black) and THC (purple) groups received access to VEH on day 1 (**b**), VEH or THC on day 2 (**c**), and VEH on day 3 (**d**). **e**) Total gelatin consumption after 2 h of access to gelatin was plotted comparing VEH and THC treatment groups. **f**) Animal consummatory and locomotor behavior was tracked during gelatin exposure window. **g-i**) Distance traveled recorded every 5 min over the 3-day paradigm, similar as to **b-d**. **j**) Total distance traveled (cm) after 2 h of gelatin access was plotted comparing VEH and THC groups. Main effect over 2 h exposure period (**b-d**, **g-i**) measured using Two-way ANOVA with repeated measures and Sidak's, main effect on total response (**e**, **h**) measured by One-way ANOVA and Sidak's (* $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$) $N = 8-16$.

samples after 1 h of consumption, at the end of the 2 h access period, as well as 30 min (2.5 h) and 24 h (26 h) following the 2 h access period (**Figure 3a**). **Figure 3b** shows THC levels in the brain reached 500-600 pmol/g tissue between 1 h and post 2.5 h time-point and was below 50 pmol/g tissue after 24 h. Remarkably, 11-OH-THC and 11-COOH-THC levels in brain increased concomitantly to THC levels, reaching 400-500 pmol/g tissue and 200-350 pmol/g tissue, respectively, between 1 h and the post 2.5 h time-point, and both were also below 50 pmol/g tissue after 24 h. Thus, levels of both CB₁R agonists, THC, and 11-OH-THC, concomitantly peaked after 1 h of THC-E-gel consumption, a result that matches the hypolocomotion response measured starting at 40 min during the 2 h consumption period (**Figure 1**). Furthermore, THC and 11-OH-THC levels in brain tissue were lower, near zero, 24 h after the 2 h exposure, as previously reported [42, 43]. THC levels in plasma reached approximately 400 pmol/g tissue at the 1 h time-point and decreased thereafter (**Figure 3c**). Statistical comparisons between the 1 h and 2 h exposure periods were limited due to different treatment paradigms, prompting the normalization of all PK values to the 1 h exposure period samples (**Figure 3d-e**). Brain samples were all increased at 2 h relative to 1 h exposure but significant differences to 1 h exposure was only found at the 26 h collection time point (**Figure 3d**, One-way ANOVA, $F_{3,139} = 14.03$, $p < 0.001$, Sidak's). Alternatively, plasma samples were significantly decreased at 2 h for THC and COOH-THC while all three compounds were significantly decreased at the 26 h collection time point (**Figure 3d**, One-way ANOVA, $F_{3,141} = 35.23$, $p < 0.001$, Sidak's). Correlation of PK findings with cannabimimetic triad results did not reveal any significant relationships. Note that 11-OH-THC and 11-COOH-THC levels peaked after 2 h of consumption which contrasts with the early onset hypolocomotion response measured in **Figure 1** after 40 min of gelatin access. Thus, PK analysis of high concentration THC-E-gel consumption demonstrates parallel accumulation of THC and 11-OH-THC in the brain, a unique profile that differs compared to previously established PK profile resulting from THC-*i.p.* injection [35, 41].

Correlating *i.p.* THC and THC-E-gel triad cannabimimetic responses predicts THC-E-gel-dependent behaviors

To further establish the pharmacological relationship between *i.p.* THC injections and THC-E-gel consumption after 1 h and 2 h consumption along with the low variability in the cannabimimetic responses triggered by both routes of administrations, we calculated “predicted THC doses” by correlating their cannabimimetic responses across experiments (**Figure 4a**). Thus, we extrapolated the relative *i.p.* dose for each cannabimimetic response triggered by consumption by plotting the cannabimimetic response following consumption onto the dose-response curve of THC-*i.p.* as reference (**Figure 4b-d**). **Figure 4b-d** also shows that 1 h access to high concentration THC-E-gel triggered greater cannabimimetic responses compared to 2 h access. Consequently, this resulted in a higher “predicted *i.p.* dose” shown by dotted lines tracked to the *i.p.* dose-response curves. Of note, 1 h access to high dose THC-E-gel triggered stronger hypolocomotion and reduction in core body temperature corresponding to 10.3 and 11.6 mg/kg THC *i.p.*, respectively, and analgesia corresponding to 4.5 mg/kg THC *i.p.* (**Figure 4b-d**). By contrast, 2 h access to high concentration THC-E-gel triggered a comparable response in the three cannabimimetic behaviors corresponding to 3-4 mg/kg THC *i.p.* (**Figure 4b-d**). **Figure 4e** illustrates the predictive value of these calculations, and the larger variability for the 1 h access predicted dose of 8.8 ± 2.2 mg/kg *i.p.* and 3.7 ± 0.3 mg/kg *i.p.* for 2 h access, a 2.4-fold higher predicted dose after 1 h access. The variability between the cannabimimetic response for the 1 h access results suggest that a difference in the PK profile of THC at 1 h compared to 2 h access (see **Figure 3**). Together, these results indicate that consumption of high dose THC-E-gel triggers strong cannabimimetic responses, comparable to *i.p.* injections of THC between 4-12 mg/kg, although this is not necessarily adaptable to all behavioral readouts.




Figure 3

Consumption of THC-E-gel results in concomitant increases in the levels of THC and its metabolites in brain tissue

a) Diagram outlining gelatin exposure paradigm where blood and brain samples were collected immediately following 1 h and at 2, 2.5, and 26 hours from the beginning of 2 h access to 10mg/15ml THC-E-gel. **b)** Brain concentration of THC, 11-OH-THC, and COOH-THC after E-gel exposure, 1 h access is separated due to a reduced total access time to THC-E-gel compared to the other time points. **c)** Plasma concentrations for the three compounds plotted similarly to **b**. **d-e)** PK concentrations in brain (**d**) and plasma (**e**) normalized to the 1 h access period. Statistical comparison to 1 h Two-way ANOVA, Sidak's, * $p < 0.05$, ** $p < 0.01$, and *** $p < 0.001$, $N = 8-15$.




Figure 4

Correlating *i.p.* THC and THC-E-gel triad cannabimimetic responses predicts THC-E-gel-dependent behaviors.

a) Diagram of 1 h and 2 h THC-E-gel exposure and *i.p.* administration with behavioral tests. **b-d)** Cannabimimetic responses after THC administration by *i.p.* and subsequent dose-response curve in grey. Responses after 1 h or 2 h exposure to 10 mg THC-E-gel are plotted with dotted lines tracking to relative THC-*i.p.* dose response. **e)** Predicted *i.p.* dose after 1 h and 2 h THC-E-gel exposure window from all three triad behaviors.

THC-E-gel consumption and THC *i.p.* injections induce sex-dependent changes in acoustic startle responses

Acoustic startle responses in mice represents a well-established preclinical approach to evaluate an unconditional reflex characterized by the rapid contraction of muscles to a sudden and intense startling stimulus. It is an especially useful measure in preclinical research as it is consistent across species and involves simple neural circuitry in sensorimotor gating [44]. It is known that *i.p.* injection of THC (6 and 10 mg/kg) reduces acoustic startle in male mice [22,34,45]. Thus, whether acute startle response is affected in a sex-dependent manner and by lower dose THC delivered *i.p.* or via oral consumption remains unknown. Here we compared the effect of THC-E-gel consumption and THC *i.p.* injections on acute acoustic startle in male and female mice. Acute startle responses were measured as the peak velocity of startles (Vmax) using an accelerometer and following audible tones of 80, 90, 100, 105, 110, and 120 dB delivered either 1 h after *i.p.* administration of THC (from 0.1 to 10 mg/kg) or immediately after access to THC-E-gel (10 mg/15 ml) (Figure 5a). THC administration via *i.p.* injection induced a significantly increased startle response in males at 1 and 5 mg/kg with a trend decrease at 10 mg/kg, and only a significantly decreased startle response in females at 10 mg/kg (Figure 5b-c, males: v. VEH Two-way ANOVA $F_{4,122} = 13.89$, $p < 0.001$, Sidak's; females: v. VEH Two-way ANOVA $F_{4,116} = 6.76$, $p < 0.001$, Sidak's). Figure 5d shows the male and female startle responses that occurred at the 120 dB tone exposures and follows an inverted U shape characterized by: 1] increased acute startle response at 1 and 5 mg THC (*i.p.*) in males, 2] absence of such response in females and 3] a comparable reduction in acute startle response in both male and female at 10 mg THC (*i.p.*) in males and females (Two-way ANOVA $F_{3,23} = 26.66$, $p < 0.001$, Sidak's).

THC-E-gel consumption by males and females also triggered a sex-dependent startle response. Figure 5e-f show that only males that were allowed access for 2 h to THC-E-gel exhibited an increase in acute startle response (2.2-fold increase) (males: Two-way ANOVA $F_{2,70} = 26.85$, $p < 0.001$, Sidak's). Further analysis of the relationship between THC-E-gel consumption and modification of the acute startle response delivered at 120 dB resulted in a significant correlation (Figure 5g, $p = 0.05$).

Finally, we sought to determine whether the predicted dose calculations from Figure 4e could be applied to the *i.p.* THC acoustic startle response dataset to test the accuracy and generalizability of the dose-prediction model. Specifically, we plotted the predicted doses of 3.7 and 8.8 mg/kg *i.p.* (from Figure 4e) on to Figure 5d depicting the acoustic startle response measured at 120dB resulting from *i.p.* injections (Supplemental Figure S5a,b). This produced predicted startle responses of: 310 cm/min for 1 h consumption and 688 cm/min for 2 h consumption for females, as well as 558 cm/min for 1 h consumption and 1733 cm/min for 2 h consumption for males. We then plotted the measured acute acoustic response (Vmax, 120 dB tone) following THC consumption in Figure 5h-i, as well as the predicted acute startle responses (dashed lines) from Figure 5d (Supplemental Figure S5a-c shows methodology). The predicted acute startle responses in males exposed to 10 mg/15 ml THC-E-gel for 1 and 2 h access was close to, or within, the standard error of the measured startle response following THC-E-gel for 1 and 2 h access (Figure 5h-i). This dose-prediction model demonstrates the reliability of voluntary THC-E-gel consumption as a behavioral paradigm to produce consistent cannabimimetic responses across different experimental modalities.

Discussion

Here we report a novel experimental approach that enables the behavioral impact of voluntary oral consumption of high dose THC by adult mice. Access to E-gel for 2 h over a two-day period incentivizes robust consumption, and at the highest dose tested here (10 mg/15 ml), mice of both sexes consumed ~30 mg/kg THC in 2 h on the second day. Acute consumption of THC triggers




Figure 5

Sex-dependent acoustic startle responses after *i.p.* injection of THC and high concentration THC-E-gel consumption

a) Diagram of THC-E-gel exposure or *i.p.* administration followed by acoustic startle response behavioral testing. **b-c)** Male and female acoustic startle responses after *i.p.* administration of THC in response to escalating tones (80, 90, 100, 105, 110, and 120dB) following *i.p.* administration of THC in males (**b**) and females (**c**). **d)** Male and female acoustic startle dose-responses to a 120dB tone after *i.p.* THC administration. Results are mean $\pm$ S.E.M. One-way ANOVA, Sidak's comparing VEH and *i.p.* THC dose between males and females $**p < 0.01$, and $***p < 0.001$, $N = 6-11$. **e-f)** Male and female acoustic startle responses after 1 h or 2 h THC E-gel exposure in response to escalating tones (80, 90, 100, 105, 110, and 120dB). **g)** THC dose consumption based on grams consumed and individual body weight correlated with individual acoustic startle response after 2 h exposure. **h-i)** Startle response to a 120dB tone for males (**h**) and females (**i**) after 1 h or 2 h access to THC E-gel. Predicted doses calculated from a second order polynomial of *i.p.* dose responses are plotted to show the consistency in predicted dose response after E-gel exposure.

commonly established cannabimimetic responses, the potencies of which were right shifted compared to the responses measured with *i.p.* injections. Furthermore, we discovered that acute consumption of 10 mg/15 ml THC-E-gel increases the acoustic startle response in males and not in females; whereas *i.p.* injection of THC triggers a dose-dependent, inverse U-shaped, impairment of acoustic startle response that was also more pronounced in males than females. Our study provides important translational results at two levels: voluntary consumption of THC by rodents and its sex-dependent impact on acoustic startle response as a measure for psychomotor reflexive behavior.

Mice of both sexes consumed similar amounts of VEH-CTR-gel and VEH-E-gel, and none consumed more than 20% of their daily caloric intake indicating comparable consumption behaviors. However, consumption of high concentration THC-CTR-gel (4 mg) was inconsistent, and 41% of the mice completely avoided consumption (as assessed by an unbroken gelatin surface at the end of the 2 h access period) (**Figure 1c**). By contrast, consumption of THC-E-gel (10 mg, i.e., 2.5X more concentrated) was more consistent with a total consumption rate of 0.95 g/2 h (**Figure 1d**). This difference in consumption between THC-CTR-gel (4 mg/15 ml) and THC-E-gel (10 mg/15 ml) is likely due to the chocolate flavoring in Ensure™ that masks the strong odor and bitter taste of high-concentration THC and its aversive properties. At higher doses of THC-E-gel exposure, we found more variability in dose consumed (**Figure 1e**), a consumption behavior similar between sexes (**Supplemental Figure S1b**). Future studies of such increased variability at even higher doses of THC may reveal differences in absorption or metabolism for example. Significantly, mice that consumed the higher dose THC-E-gel on Day 2 consumed remarkably less VEH-E-gel on Day 3 (**Supplementary Figure S2c**). This decrease in consumption is likely due to the development of aversive conditioned associations to higher dose THC. Thus, the THC-E-gel experimental approach reported here also enables the study of aversive memory to voluntary oral consumption of high dose THC.

I.p. injection of THC induces hypolocomotion, analgesia, and hypothermia in mice with different median effective doses (ED₅₀, 1.3, 3.9 and 14.4 mg/kg, respectively) (**Figure 2b-d**). By comparison, 1 h access to 10 mg THC-E-gel produced cannabimimetic responses that paralleled the ED₅₀ of *i.p.* injections and are equivalent to an *i.p.* dose of ~9 mg/kg. Also, 1 h access to 10 mg THC-E-gel evoked a more pronounced cannabimimetic response compared to 2 h access, agreeing with prior studies which have shown that oral gavage increases brain peak concentration of THC 1-2 h after administration [46]. Oral consumption also increases 11-OH-THC levels in the brain with comparable kinetics and concentration as THC, and the levels of both cannabinoids decrease in parallel (**Figure 3b-c**). Considering that ~600 pmol/g of THC and 11-OH-THC is roughly equivalent to 3 nM of both compounds in the brain that persists over several hours, and both activate CB₁R with comparable potencies, our results suggest that the accumulation of both THC and 11-OH-THC in the brain might contribute to cannabimimetic responses [47]. Because of the experimental design implemented for this study, we did not determine if variation in the time course of distinct cannabimimetic response we different following consumption. Thus, future studies that prioritize behavioral responses at multiple time points following consumption of THC using E-gel results might reveal differences in the dynamics of onset and decay in cannabimimetic responses.

We found that oral consumption of THC-E-gel produced a higher brain concentration of the primary metabolite 11-OH-THC in the brain compared to previously published concentrations after *i.p.* administration [41]. This suggests oral administration may modify the accumulation of 11-OH-THC or its metabolism in the brain. Both males and females were studied for all pharmacokinetic timepoints, and we found no significant sexual differences (**Supplementary Tables S6,7**). Finally, considering that voluntary oral consumption of 10 mg/15 ml THC results in nanomolar concentrations of THC and 11-OH-THC for several hours, the time-dependent reduction in cannabimimetic response that follows their maximal response may also be due either to CB₁R desensitization/tolerance or to redistribution of the drug within brain parenchyma.

An *i.p.* injection of THC 6 and 10 mg/kg in male mice reduces acoustic startle behaviors [34 [↗](#), 45 [↗](#)]. We show here that THC-*i.p.* induces a dose-dependent biphasic behavioral response that is more pronounced in males than females, demonstrating sex-dependent sensorimotor behaviors, and confirming that THC impacts neurocognitive function in a sex-dependent manner (**Supplementary Figure S3**) [48 [↗](#)-50 [↗](#)]. THC-E-gel (10 mg/15 ml) consumption also increased the response to acoustic startle preferentially in males compared to females. Whether the dose of THC formulated in E-gel can be increased to levels that remain palatable to mice and might trigger the pronounced reduced acoustic startle measured with 10 mg THC injection *i.p.* remains an open question.

Analysis of the behavioral responses following *i.p.* injection and consumption of THC-E-gel enabled us to propose a model that correlates the doses of THC capable of producing comparable behavioral responses, emphasizing the robustness of this experimental approach. Thus, the flexibility of the THC-E-gel experimental approach may extend its utility as a substitute for traditional *i.p.* injections, better bridging the translational gap between preclinical investigations and human use. For example, the THC-E-gel experimental model can be easily modified and implemented to measure, in a less invasive manner, the impact of oral THC consumption on additional mouse behaviors, including self-administration and preference/aversion, paradigms that require multiple treatment regimens.

In conclusion, we report a new experimental approach that achieves robust voluntary oral consumption of THC in adult mice by formulating THC in a chocolate-flavored sweetened E-gel. Given the recent rise in use of *Cannabis* products that contain high doses of THC such as edibles [51 [↗](#)], this voluntary consumption model allows the study of its effect on translational relevant behaviors, including sex-dependent psychomotor reflexes in mice.

Author Contributions

A.E., D.P., M.B., N.S., and B.L. conceived and designed the study. A.E., F.U., A.T., D.S., and A.S. acquired the data. A.E., F.U., A.T., D.S., and A.S. performed the analysis. All authors have edited and approved the final manuscript.

Funding

NIDA F31 DA055448-01 to A.E. with N.S. and M.B. Research support from the UW Addictions, Drug & Alcohol Institute (ADAI) Small Grants Program and the Washington State Dedicated Cannabis Fund to A.E., NCCIH R01 AT011524-01A1 to B.L., NIDA R21 DA051558-02 to N.S. and B.L., NIDA R37 DA033396-10 to M.R.B., Center of Excellence in Neurobiology of Addiction, Pain, and Emotion NIDA P30 DA048736 to M.R.B. (Charles Chavkin PI), Center of Excellence ICAL (Impact of Cannabinoids across the Lifespan) P50DA044118-01 to D.P.

Competing Interests

The authors have nothing to disclose.

References

- 1 Hasin DS, Shmulewitz D, Sarvet AL (2019) **Time trends in US cannabis use and cannabis use disorders overall and by sociodemographic subgroups: a narrative review and new findings** *The American journal of drug and alcohol abuse* **45**:623–43
- 2 Compton WM, Han B, Jones CM, Blanco C, Hughes A. (2016) **Marijuana use and use disorders in adults in the USA, 2002–14: analysis of annual cross-sectional surveys** *The Lancet Psychiatry* **3**:954–64
- 3 Carlini BH, Schauer GL (2022) **Cannabis-only use in the USA: prevalence, demographics, use patterns, and health indicators** *Journal of cannabis research* **4**:1–8
- 4 Martin-Santos R, a, Crippa J, Batalla A, Bhattacharyya S, Atakan Z, Borgwardt S, et al. (2012) **Acute effects of a single, oral dose of d9-tetrahydrocannabinol (THC) and cannabidiol (CBD) administration in healthy volunteers** *Current pharmaceutical design* **18**:4966–79
- 5 Zuurman L, Roy C, Schoemaker R, Hazekamp A, Den Hartigh J, Bender J, et al. (2008) **Effect of intrapulmonary tetrahydrocannabinol administration in humans** *Journal of psychopharmacology* **22**:707–16
- 6 Morgan CJ, Freeman TP, Hindocha C, Schafer G, Gardner C, Curran HV (2018) **Individual and combined effects of acute delta-9-tetrahydrocannabinol and cannabidiol on psychotomimetic symptoms and memory function** *Translational psychiatry* **8**:1–10
- 7 Hollister LE, Gillespie H (1973) **Delta-8-and delta-9-tetrahydrocannabinol; Comparison in man by oral and intravenous administration** *Clinical Pharmacology & Therapeutics* **14**:353–57
- 8 Hollister LE (1970) **Tetrahydrocannabinol isomers and homologues: contrasted effects of smoking** *Nature* **227**
- 9 Weinstein A, Brickner O, Lerman H, Greemland M, Bloch M, Lester H, et al. (2008) **Brain imaging study of the acute effects of Δ 9-tetrahydrocannabinol (THC) on attention and motor coordination in regular users of marijuana** *Psychopharmacology* **196**:119–31
- 10 Weinstein A, Brickner O, Lerman H, Greemland M, Bloch M, Lester H, et al. (2008) **A study investigating the acute dose—response effects of 13 mg and 17 mg Δ 9-tetrahydrocannabinol on cognitive—motor skills, subjective and autonomic measures in regular users of marijuana** *Journal of psychopharmacology* **22**:441–51
- 11 Hindley G, Beck K, Borgan F, Ginestet CE, McCutcheon R, Kleinloog D, et al. (2020) **Psychiatric symptoms caused by cannabis constituents: a systematic review and meta-analysis** *The Lancet Psychiatry* **7**:344–53
- 12 Barrett FS, Schlienz NJ, Lembeck N, Waqas M, Vandrey R (2018) **“Hallucinations” following acute cannabis dosing: a case report and comparison to other hallucinogenic drugs** *Cannabis and Cannabinoid Research* **3**:85–93
- 13 Lira MC, Heeren TC, Buczek M, Blanchette JG, Smart R, Pacula RL, et al. (2021) **Trends in cannabis involvement and risk of alcohol involvement in motor vehicle crash fatalities in the United States, 200012018** *American journal of public health* **111**:1976–85

- 14 Moore TH, Zammit S, Lingford-Hughes A, Barnes TR, Jones PB, Burke M, et al. (2007) **Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review** *The Lancet* **370**:319–28
- 15 Holtzman D, Lovell RA, Jaffe JH, Freedman DX (1969) **1- Δ^9 -tetrahydrocannabinol: neurochemical and behavioral effects in the mouse** *Science* **163**:1464–67
- 16 Beardsley PM, Scimeca JA, Martin BR (1987) **Studies on the agonistic activity of! D9-21-tetrahydrocannabinol in mice, dogs and rhesus monkeys and its interactions with! D-9-tetrahydrocannabinol** *The Journal of Pharmacology and Experimental Therapeutics*
- 17 Metna-Laurent M, Mondésir M, Grel A, Vallée M, Piazza PV (2017) **Cannabinoid-induced tetrad in mice** *Current Protocols in Neuroscience* **80**:9–9
- 18 Siemens AJ, Doyle OL (1979) **Cross-tolerance between Δ^9 -tetrahydrocannabinol and ethanol: the role of drug disposition** *Pharmacology Biochemistry and Behavior* **10**:49–55
- 19 Ruiz C, Torrens A, Lallai V, Castillo E, Manca L, Martinez M, et al. (2021) **Pharmacokinetic and pharmacodynamic properties of aerosolized (“vaped”) THC in adolescent male and female rats** *Psychopharmacology* **238**:3595–605
- 20 Kasten CR, Zhang Y, Boehm SL (2019) **Acute cannabinoids produce robust anxiety-like and locomotor effects in mice, but long-term consequences are age-and sex-dependent** *Frontiers in behavioral neuroscience* **13**
- 21 Ibarra-Lecue I, Mollinedo-Gajate I, Meana JJ, Callado LF, Diez-Alarcia R, Urigüen L (2018) **Chronic cannabis promotes pro-hallucinogenic signaling of 5-HT2A receptors through Akt/mTOR pathway** *Neuropsychopharmacology* **43**:2028–35
- 22 Long LE, Chesworth R, Huang X-F, McGregor IS, Arnold JC, Karl T (2010) **A behavioural comparison of acute and chronic Δ^9 -tetrahydrocannabinol and cannabidiol in C57BL/6JArc mice** *International Journal of Neuropsychopharmacology* **13**:861–76
- 23 Boucher AA, Hunt GE, Micheau J, Huang X, McGregor IS, Karl T, et al. (2011) **The schizophrenia susceptibility gene neuregulin 1 modulates tolerance to the effects of cannabinoids** *International Journal of Neuropsychopharmacology* **14**:631–43
- 24 Hoffman HS, Ison JR (1980) **Reflex modification in the domain of startle: I. Some empirical findings and their implications for how the nervous system processes sensory input** *Psychological review* **87**
- 25 Burgdorf CE, Jing D, Yang R, Huang C, Hill MN, Mackie K, et al. (2020) **Endocannabinoid genetic variation enhances vulnerability to THC reward in adolescent female mice** *Science Advances* **6**
- 26 Lepore M, Vorel SR, Lowinson J, Gardner EL (1995) **Conditioned place preference induced by Δ^9 -tetrahydrocannabinol: comparison with cocaine, morphine, and food reward** *Life sciences* **56**:2073–80
- 27 Kruse LC, Cao JK, Viray K, Stella N, Clark JC (2019) **Voluntary oral consumption of Δ^9 -tetrahydrocannabinol by adolescent rats impairs reward-predictive cue behaviors in adulthood** *Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology*

- 28 Abraham AD, Leung EJ, Wong BA, Rivera ZM, Kruse LC, Clark JJ, et al. (2020) **Orally consumed cannabinoids provide long-lasting relief of allodynia in a mouse model of chronic neuropathic pain** *Neuropsychopharmacology* **45**:1105–14
- 29 Smoker MP, Mackie K, Lapish CC, Boehm SL (2019) **Self-administration of edible Δ9-tetrahydrocannabinol and associated behavioral effects in mice** *Drug and alcohol dependence* **199**:106–15
- 30 Kruse LC, Cao JK, Viray K, Stella N, Clark JJ (2019) **Voluntary oral consumption of Δ9-tetrahydrocannabinol by adolescent rats impairs reward-predictive cue behaviors in adulthood** *Neuropsychopharmacology* **44**:1406–14
- 31 Barrus DG, Lefever TW, Wiley JL (2018) **Evaluation of reinforcing and aversive effects of voluntary Δ9-tetrahydrocannabinol ingestion in rats** *Neuropharmacology* **137**:133–40
- 32 Ventura R, Morrone C, Puglisi-Allegra S (2007) **Prefrontal/accumbal catecholamine system determines motivational salience attribution to both reward-and aversion-related stimuli** *Proceedings of the National Academy of Sciences* **104**:5181–86
- 33 Barbano MF, Castañé A, Martín-García E, Maldonado R (2009) **Delta-9-tetrahydrocannabinol enhances food reinforcement in a mouse operant conflict test** *Psychopharmacology* **205**:475–87
- 34 Nagai H, Egashira N, Sano K, Ogata A, Mizuki A, Mishima K, et al. (2006) **Antipsychotics improve Δ9-tetrahydrocannabinol-induced impairment of the prepulse inhibition of the startle reflex in mice** *Pharmacology Biochemistry and Behavior* **84**:330–36
- 35 Vozella V, Zibardi C, Ahmed F, Piomelli D (2019) **Fast and sensitive quantification of Δ9-tetrahydrocannabinol and its main oxidative metabolites by liquid chromatography/tandem mass spectrometry** *Cannabis and Cannabinoid Research* **4**:110–23
- 36 Schindler AG, Tsutsui KT, Clark JJ (2014) **Chronic alcohol intake during adolescence, but not adulthood, promotes persistent deficits in risk-based decision making** *Alcoholism: clinical and experimental research* **38**:1622–29
- 37 Falenski KW, Thorpe AJ, Schlosburg JE, Cravatt BF, Abdullah RA, Smith TH, et al. (2010) **FAAH^{-/-} mice display differential tolerance, dependence, and cannabinoid receptor adaptation after Δ9-tetrahydrocannabinol and anandamide administration** *Neuropsychopharmacology* **35**:1775–87
- 38 Varvel SA, Bridgen DT, Tao Q, Thomas B, Martin B, Lichtman A (2005) **Δ9-Tetrahydrocannabinol accounts for the antinociceptive, hypothermic, and cataleptic effects of marijuana in mice** *Journal of Pharmacology and Experimental Therapeutics* **314**:329–37
- 39 Ettaro R, Laudermilk L, Clark SD, Maitra R (2020) **Behavioral assessment of rimonabant under acute and chronic conditions** *Behavioural brain research* **390**
- 40 Wright F, Rodgers R (2013) **Low dose naloxone attenuates the pruritic but not anorectic response to rimonabant in male rats** *Psychopharmacology* **226**:415–31
- 41 Torrens A, Vozella V, Huff H, McNeil B, Ahmed F, Ghidini A, et al. (2020) **Comparative pharmacokinetics of Δ9-tetrahydrocannabinol in adolescent and adult male mice** *Journal of Pharmacology and Experimental Therapeutics* **374**:151–60

- 42 Kreuz DS, Axelrod J (1973) **Delta-9-tetrahydrocannabinol: localization in body fat** *Science* **179**:391–93
- 43 Johansson E, Norén K, Sjövall J, Halldin MM (1989) **Determination of Δ^1 -tetrahydrocannabinol in human fat biopsies from marihuana users by gas chromatography-mass spectrometry** *Biomedical Chromatography* **3**:35–38
- 44 Pantoni MM, Herrera GM, Van Alstyne KR, Anagnostaras SG (2020) **Quantifying the acoustic startle response in mice using standard digital video** *Frontiers in Behavioral Neuroscience* **14**
- 45 Tournier BB, Ginovart N (2014) **Repeated but not acute treatment with Δ^9 -tetrahydrocannabinol disrupts prepulse inhibition of the acoustic startle: Reversal by the dopamine D2/3 receptor antagonist haloperidol** *European Neuropsychopharmacology* **24**:1415–23
- 46 Deiana S, Watanabe A, Yamasaki Y, Amada N, Arthur M, Fleming S, et al. (2012) **Plasma and brain pharmacokinetic profile of cannabidiol (CBD), cannabidivarin (CBDV), Δ^9 -tetrahydrocannabivarin (THCV) and cannabigerol (CBG) in rats and mice following oral and intraperitoneal administration and CBD action on obsessive-compulsive behaviour** *Psychopharmacology* **219**:859–73
- 47 Dinis-Oliveira RJ. (2016) **Metabolomics of Δ^9 -tetrahydrocannabinol: implications in toxicity** *Drug metabolism reviews* **48**:80–87
- 48 Cha YM, Jones KH, Kuhn CM, Wilson WA, Swartzwelder HS (2007) **Sex differences in the effects of Δ^9 -tetrahydrocannabinol on spatial learning in adolescent and adult rats** *Behavioural pharmacology* **18**:563–69
- 49 Harte LC, Dow-Edwards D (2010) **Sexually dimorphic alterations in locomotion and reversal learning after adolescent tetrahydrocannabinol exposure in the rat** *Neurotoxicology and teratology* **32**:515–24
- 50 Gur RC, Richard J, Calkins ME, Chiavacci R, Hansen JA, Bilker WB, et al. (2012) **Age group and sex differences in performance on a computerized neurocognitive battery in children age 8– 21** *Neuropsychology* **26**
- 51 Freeman TP, Craft S, Wilson J, Stylianou S, ElSohly M, Di Forti M, et al. (2021) **Changes in delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) concentrations in cannabis over time: systematic review and meta-analysis** *Addiction* **116**:1000–10

Article and author information

Anthony English

Departments of Pharmacology, University of Washington, Seattle WA 98195, UW Center of Excellence in Neurobiology of Addiction, Pain, and Emotion (NAPE), University of Washington, Seattle WA 98195, Center for Cannabis Research, University of Washington, Seattle WA 98195

Fleur Uittenbogaard

Departments of Pharmacology, University of Washington, Seattle WA 98195, UW Center of Excellence in Neurobiology of Addiction, Pain, and Emotion (NAPE), University of Washington, Seattle WA 98195, Center for Cannabis Research, University of Washington, Seattle WA 98195

Alexa Torrens

Department of Anatomy & Neurobiology, University of California Irvine, Irvine CA

Dennis Sarroza

Departments of Pharmacology, University of Washington, Seattle WA 98195

Anna Slaven

Departments of Pharmacology, University of Washington, Seattle WA 98195, UW Center of Excellence in Neurobiology of Addiction, Pain, and Emotion (NAPE), University of Washington, Seattle WA 98195

Danielle Piomelli

Department of Anatomy & Neurobiology, University of California Irvine, Irvine CA

Michael R. Bruchas

Departments of Pharmacology, University of Washington, Seattle WA 98195, UW Center of Excellence in Neurobiology of Addiction, Pain, and Emotion (NAPE), University of Washington, Seattle WA 98195, Center for Cannabis Research, University of Washington, Seattle WA 98195, Department of Anatomy & Neurobiology, University of California Irvine, Irvine CA

Nephi Stella

Departments of Pharmacology, University of Washington, Seattle WA 98195, UW Center of Excellence in Neurobiology of Addiction, Pain, and Emotion (NAPE), University of Washington, Seattle WA 98195, Center for Cannabis Research, University of Washington, Seattle WA 98195, Psychiatry & Behavioral Sciences, University of Washington, Seattle WA 98195

For correspondence: nstella@uw.edu

Benjamin B. Land

Departments of Pharmacology, University of Washington, Seattle WA 98195, UW Center of Excellence in Neurobiology of Addiction, Pain, and Emotion (NAPE), University of Washington, Seattle WA 98195, Center for Cannabis Research, University of Washington, Seattle WA 98195

For correspondence: bbl2@uw.edu

Copyright

© 2023, English et al.

This article is distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use and redistribution provided that the original author and source are credited.

Editors

Reviewing Editor

Robert Laprairie

University of Saskatchewan, Canada

Senior Editor

Kate Wassum

University of California, Los Angeles, Los Angeles, United States of America

Reviewer #1 (Public Review):**Summary:**

This manuscript describes the development of an oral THC consumption model in mice where THC is added to a chocolate flavored gelatin. The authors compared the effects of THC consumed in this highly palatable gelatin (termed E-gel) to THC dissolved in a less palatable gelatin (CTR-gel), and to i.p. injections of multiple doses of THC, on the classic triad of CB1R dependent behaviors (hypolocomotion, antinociception, and body temperature).

The authors found that they could achieve consumption of higher concentrations of THC in the E-gel than the CTR-gel, and that this led to larger total dose exposure and decreases in locomotor activity, antinociception, and body temperature reductions similar to 3-4 mg/kg THC when tested after 2 hour consumption and roughly 10 mg/kg if tested immediately after 1 hour consumption. The majority of THC E-gel consumption was found to occur in the first hour on the first exposure day. THC E-gel consumption was lower than VEH E-gel consumption and this persisted on a subsequent consumption day, suggesting that the animals may form a taste aversion and that THC at the dose consumed likely has aversive properties, consistent with the literature on i.p. dosing. The authors also report the pharmacokinetics in brain and plasma of THC and metabolites after 1 or 2 hour consumption, finding high levels of THC in the brain that begins to dissipate at 2.5 hours is gone 24 hours later. Finally, the authors tested THC effects on the acoustic startle response and found an inverted dose response that was more pronounced in males than females after i.p. dosing and a greater startle response in males after E-gel dosing.

Overall, the authors find that voluntary oral consumption of THC can achieve levels of intake that are consistent with the present and prior reported literature on i.p. dosing.

Strengths:

The strengths of the article include a direct comparison of voluntary oral THC consumption to noncontingent i.p. administration, the use of multiple THC doses and oral THC formulations, the inclusion of multiple assays of cannabinoid agonist effects, and the inclusion of males and females. Additional strengths include monitoring intake over 10 minute intervals and validating that effects are CB1R dependent via antagonist studies.

Weaknesses:

1. The abstract does not discuss the reduction of E-gel consumption that occurs after multiple days of exposure to the THC formulation, but rather implies that a new model for chronic oral self-administration has been developed. Given that only two days of consumption was assessed, it is not clear if the model will be useful to determine THC effects beyond the acute measures presented here. The abstract should clarify that there was evidence of reduced consumption/aversive effects with repeated exposures.
2. In the results section, the authors sometimes describe effects in terms of the concentration of gel as opposed to the dose consumed in mg/kg, which can make interpretation difficult. For example, the text describing Figure 1i states that significant effects on body temperature were achieved at 4 mg CTR-gel and 5 mg THC-gel, but were essentially equivalent doses consumed? It would be helpful to describe what average dose of THC produced effects given that consumption varied within each group of mice assigned to a particular concentration.
3. The description of the PK data in Figure 3 did not specify if sex differences were examined. Prior studies have found that males and females can exhibit stark differences in brain and plasma levels of THC and metabolites, even when behavioral effects are similar. However, this does depend on species, route, timing of tissue collection. It would be helpful to describe the PK profile of males and females separately.
4. In Figure 5, it is unclear how the predicted i.p. THC dose could be 30 mg/kg when 30 mg/kg

was not tested by the i.p. route according to the figure, and if it had been it would have likely been almost zero acoustic startle, not the increased startle that was observed in the 2 hr gel group. It seems more likely that it would be equivalent to 3 mg/kg i.p. Could there be an error in the modeling, or was it based on the model used for the triad effects? This should be clarified.

- <https://doi.org/10.7554/eLife.89867.2.sa2>

Reviewer #2 (Public Review):

Summary:

The work fruitfully adds to the tools to study cannabinoid action and pharmacology specifically, but also this method is applicable to other drugs, in particular, if lipophilic in nature.

Strengths:

The addition of chocolate flavor overcomes aversive reactions which are often experienced in pharmacological treatments, leading to possible caveats in the interpretation of the behavioral outcomes.

Weaknesses:

Certainly, more THC mediated behavioral outcomes could have been tested, but the work presents a proof-of-concept study to investigate acute THC treatment. It would have been interesting if this application form is also possible for chronic treatment regimen.

- <https://doi.org/10.7554/eLife.89867.2.sa1>

Reviewer #3 (Public Review):

Summary: This manuscript explores the development of a rodent voluntary oral THC consumption model. The authors use the model to demonstrate that similar effect levels of THC can be observed to what has previously been described for i.p. THC administration.

Strengths: Overall this is an interesting study with compelling data presented. There is a growing need within the field of cannabinoid research to explore more 'realistic' routes of cannabinoid administration, such as oral consumption or inhalation. The evidence presented here shows the utility of this oral administration model.

Weaknesses: The main weaknesses of the manuscript revolve around clarification of the Methods section. All of these weaknesses are described in the "Recommendations to authors" section. Revising the manuscript would account for many of these weaknesses.

- <https://doi.org/10.7554/eLife.89867.2.sa0>

Author Response

The following is the authors' response to the original reviews.

We thank the reviewers for their thorough reading of the manuscript and insightful comments. We have responded to both the "public review" and the "recommendations" and feel that the manuscript is now significantly strengthened.

Public Review comments

Reviewer #1:

Weaknesses:

1. *The abstract does not discuss the reduction of E-gel consumption that occurs after multiple days of exposure to the THC formulation, but rather implies that a new model for chronic oral self-administration has been developed. Given that only two days of consumption was assessed, it is not clear if the model will be useful to determine THC effects beyond the acute measures presented here. The abstract should clarify that there was evidence of reduced consumption/aversive effects with repeated exposures.*

Thank you for your observation. We have added language to address this in the manuscript and the abstract. The model developed in the manuscript is an acute exposure model, with the intention of further chronic exposure adaptations to be developed separately (page 2, line 29).

1. *In the results section, the authors sometimes describe effects in terms of the concentration of gel as opposed to the dose consumed in mg/kg, which can make interpretation difficult. For example, the text describing Figure 1i states that significant effects on body temperature were achieved at 4 mg CTR-gel and 5 mg THC-gel, but were essentially equivalent doses consumed? It would be helpful to describe what average dose of THC produced effects given that consumption varied within each group of mice assigned to a particular concentration.*

We thank the reviewer for this comment and have edited our text to clarify our results. For example, this point is further emphasized by the correlation of the data in Figure 11-n showing the relationship between individual consumption and behavioral readouts (page 11, line 225-226).

1. *The description of the PK data in Figure 3 did not specify if sex differences were examined. Prior studies have found that males and females can exhibit stark differences in brain and plasma levels of THC and metabolites, even when behavioral effects are similar. However, this does depend on species, route, timing of tissue collection. It would be helpful to describe the PK profile of males and females separately.*

We did compare sex dependent effects and found no significant effects after THC E-gel consumption. We've added additional language to address this point in the discussion (Supplementary tables T1 and T2).

1. *In Figure 5, it is unclear how the predicted i.p. THC dose could be 30 mg/kg when 30 mg/kg was not tested by the i.p. route according to the figure, and if it had been it would have likely been almost zero acoustic startle, not the increased startle that was observed in the 2 hr gel group. It seems more likely that it would be equivalent to 3 mg/kg i.p. Could there be an error in the modeling, or was it based on the model used for the triad effects? This should be clarified.*

We apologize for the confusion created by that data, and it has now been updated for clarity. The original ~30mg/kg was not a predicted dose consumed, but rather an expected dose consumed based on individual male v. female consumption data in Supplemental Figure S1b. For clarity on the figure, we've instead placed dashed lines that draw attention only to the predicted startle response expected from our THC-E-gel model. We have also updated the text which hopefully makes this clearer.

Reviewer #2:*Weaknesses:*

Certainly, more THC mediated behavioral outcomes could have been tested, but the work presents a proof-of-concept study to investigate acute THC treatment.

It would have been interesting if this application form is also possible for chronic treatment regimen

We agree that a chronic treatment regimen and additional behavioral outcomes is the next, most exciting step for expanding this oral THC-E-gel consumption model, and something we are actively pursuing.

Reviewer #3:*Weaknesses:*

The main weaknesses of the manuscript revolve around clarification of the Methods section. All of these weaknesses are described in the "Recommendations to authors" section. Revising the manuscript would account for many of these weaknesses.

Thank you for carefully reading through our methodology. We have made edits according to everything brought up in the recommendation section of reviewer comments.

Recommendations for Authors**Reviewer #1:***Minor edits to the text:*

Abstract: "intraperitoneal contingent" should be "intraperitoneal noncontingent".

Line 221, this sentence needs editing for clarity.

Lines 249-250, incomplete sentence.

Line 284, the word "activity" is missing from "locomotor between mice".

Lines 299-301, incomplete sentence.

Thank you for finding these mistakes. All these recommendations have been incorporated into the final publication.

Reviewer #2:

- 1. The typical THC tetrad includes catalepsy. Why was this behavioral outcome not monitored?*

We felt that locomotion, analgesia, and body temperature were robust behavioral readouts for monitoring cannabimimetic responses and that acoustic startle served as an additional, novel means of understanding THC-E-gel effects.

- 1. Please specify the exact substrain of C57BL/6 (i.e., J or N or some other)*

C57BL/6J mice were used for the publication. This clarification has been made in the methods section.

1. *Figure S3 is not mentioned in the result part, but only in the discussion.*

Figure S3 is now referenced in the main body of the Results section.

1. *It might be interesting to follow up the issue that the individual THC consumption is considerable, as depicted in Fig. 1e (at high dose). This will presumably also lead to different behavioral responses. Or is there individual metabolism, also difference male vs. female?*

Thank you for the suggestion. We agree that the distribution of THC doses consumed (calculation based on weight) would be worth further investigating and have now included language about this (page 20, line 436). Please note that we did not find a sex difference (Supplemental Figure S1b), but it would be exciting to discover some biologically relevant cause such as individual absorption or metabolism

Reviewer #3:

Major

1. *Methods: Were the observers of experiments blinded to animal treatment? Why or why not?*

Multiple investigators performed the behavioral measurements and were not blinded to mouse treatments, but the dose consumed by each mouse remained blind. Thus, because animals consumed THC gelatin of their own volition while having ad libitum access, we performed the correlational analysis presented in Figure 1 l-n.

1. *Methods: The authors could consider relating their study design to the ARRIVE guidelines and providing a statement as to whether their study adheres to these guidelines. Related to this, were mice provided with any environmental enrichment during the study?*

We followed the ARRIVE guidelines with exception to investigator blinding (described above). Please note that mice were not provided with additional environmental enrichment during the study, a point that we specified in our methods (page 5, line 91).

1. *Methods / Results: In the Methods it is stated that the triad of cannabimimetic behaviors was measured 1 h post-injection or immediately after gelatin exposure. Why were these timepoints chosen? Perhaps this wording should be revised because measurements of cannabimimetic effects were taken several times after drug exposure. Peak i.p. drug may occur earlier than 1 h whereas peak oral drug effect is likely to occur over a longer time period (i.e., not immediately after) due to delays of absorption and first pass metabolism. Is it possible that the authors have underestimated oral drug effects by selecting these timepoints? Please discuss.*

We observed a reduction in locomotion activity starting 1 h following the beginning of exposure to the gelatin (Figure 2), suggesting initial cannabimimetic changes. Based on this observable response we chose to measure all cannabimimetic behaviors immediately following gelatin exposure. The exposure timeline for i.p. injection (1 h post-injection) was selected based on a standard published protocol (Metna-Laurent et al, 2017).

a. Pharmacodynamics: Related to this and because the aim of this paper is to establish a rodent oral dose model, could the authors discuss the need for better characterization of the time course of drug effects? For example, how might anti-nociception or locomotor activity vary following THC E-gel consumption? This is somewhat addressed in the locomotion time course in Figure 2G but could be elaborated on or discussed in more detail.

We agree that future studies should include additional time points measuring behavioral changes. This important point is now emphasized in the discussion (page 21, line 455).

b. Pharmacokinetics: Related to this point above, have the authors considered collecting blood or tissue samples from their i.p.-injected animals to assess drug pharmacokinetics as they relate to drug effect and as compared to oral THC consumption? I am not suggesting the authors conduct a completely new study for this manuscript; however, this could be raised as a future study and/or as a weakness of the current study.

We did not measure blood and tissue concentrations after i.p. administration due to the number of studies reporting these values by our co-author, Dr. Daniele Piomelli, that established these pharmacokinetic measures. Thus, we chose to reference these studies. Please note that repeating such measurements would be labor intensive, unnecessary use federal NIH resources and animals, while being very redundant to the existing literature.

c. Minor, but related to these points: In the results, page 14 line 299: the first sentence of this paragraph is confusing as written. The Reviewer recognizes that the authors are relating the pharmacokinetic work to previously published findings, but still thinks that measuring and comparing THC levels from their cohort of i.p.-injected animals would have benefitted the present study.

Thank you, this edit has been made in the manuscript.

1. Methods, Histology: The methods as described do not contain sufficient detail regarding THC and THC metabolite quantification. In addition, it is not clear from this section what Histology was performed and how (no histology results appear in the manuscript). Please add more detail to this section of the Methods.

We apologize for this typo and have corrected it in the methods section of the manuscript.

1. Methods / Results: The statistics section requires additional detail regarding the rationale for tests being performed on different datasets. In addition, a description of the curve fitting used for data in figures 1H-J, 4B-D, and S4 would be helpful to the reader.

Thank you, we have updated and provided more information regarding the curve fitting that was used in the methods and results section for the respective figure panels (page 9, line 183-184).

Minor

1. Throughout: The use of the phrase "high" dose is somewhat arbitrary and not defined relative to other doses of the THC formulation throughout the manuscript. The Reviewer suggests simply stating that THC was used, specifying the dose, or justifying in the Abstract and/or Introduction the classification of "high" based on relevant literature.

Thank you for the observation. We have removed this ambiguity by specifically mentioning the dose that was consumed (e.g., abstract page 2, line 20).

| 1. *Abstract: define "CB1" in the abstract. Although this is a common abbreviation within the field, its use should be defined.*

We have added this definition in the abstract for clarification.

| 1. *Figure 2: why are the consumption panels B, C, and D given separate labels but the locomotor data are all labeled together as panel G?*

Thank you for the observation, we have adjusted the labeling, so it is equal for both sets of panels.